Sugi Predict

Sugi Predict / Compounds / Somatostatin Receptor Ligand

Somatostatin Receptor Ligand

Somatostatin Receptor Ligand

SCHEMBL1845792

CC(O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)N)CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC1=O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SSTR1SSTR2SSTR3SSTR4SSTR5

The experimentally established mechanism targets of Somatostatin Receptor Ligand. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ SSTR1 known ✓ P30872 12/20 0.72
▸ SSTR2 known ✓ P30874 12/20 0.72
▸ SSTR4 known ✓ P31391 11/20 0.72
▸ SSTR5 known ✓ P35346 11/20 0.72
▸ SSTR3 known ✓ P32745 9/20 0.72
▸ PLAU P00749 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29368491 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin SCHEMBL29350200 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin SCHEMBL21361053 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL3046327 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL8482 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL29386529 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL12548326 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL16062971 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL31432768 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL16186775 0.92 SSTR4 (0.83) SSTR1SSTR2SSTR4SSTR5SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100566756-C Pharmaceutical composition comprising polyethylene glycol having a molecular weight of less than 600 daltons NOVARTIS AG (CH) 2009-12-09 — — CN claimed
EP-2323623-B1 PHARMACEUTICAL COMPOSITIONS NOVARTIS AG (CH) 2016-07-27 — — EP disclosed
US-9155696-B2 Pharmaceutical compositions NOVARTIS AG (CH) 2015-10-13 — — US disclosed
US-20140235555-A1 Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons NOVARTIS AG (CH) 2014-08-21 — — US disclosed
US-20130116178-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS NOVARTIS AG (CH) 2013-05-09 — — US disclosed
US-20110183905-A1 PHARMACEUTICAL COMPOSITIONS NOVARTIS AG (CH) 2011-07-28 — — US disclosed
EP-2323623-A1 PHARMACEUTICAL COMPOSITIONS Novartis AG (CH) 2011-05-25 — — EP disclosed
EP-2213307-A1 Injectable depot formulations Novartis AG (CH) 2010-08-04 — — EP disclosed
EP-2172189-A1 Pharmaceutical Compositions Novartis AG (CH) 2010-04-07 — — EP disclosed
WO-2010018159-A1 PHARMACEUTICAL COMPOSITIONS NOVARTIS AG (CH) 2010-02-18 — — WO disclosed
CN-100566756-C Pharmaceutical composition comprising polyethylene glycol having a molecular weight of less than 600 daltons NOVARTIS AG (CH) 2009-12-09 — — CN disclosed
US-20080213330-A1 Liquid solidification implants including biodegradable polymer; simplified prepatation; storage stable in prefilled syringe; negligible irritation, necrotic or toxic effects; Cushing's disease LAMBERT OLIVIER 2008-09-04 — — US disclosed
CN-1964698-A Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons NOVARTIS AG (CH) 2007-05-16 — — CN disclosed
EP-1758553-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS Novartis AG (CH) 2007-03-07 — — EP disclosed
WO-2005120453-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS NOVARTIS AG (CH) 2005-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213330-A1 Liquid solidification implants including biodegradable polymer; simplified prepatation; storage stable in prefilled syringe; negligible irritation, necrotic or toxic effects; Cushing's disease CRH, GCG, SHBG SSTR1 16/4885SSTR2 66/4885SSTR4 64/4885
US-20140235555-A1 Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons PGM2, PLG, RPL7 SSTR1 1139/4885SSTR2 895/4885SSTR4 1655/4885
US-20110183905-A1 PHARMACEUTICAL COMPOSITIONS LIPA, PGM2, LPXN SSTR1 2344/4885SSTR2 1916/4885SSTR4 2461/4885
US-20130116178-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT OF LESS THAN 600 DALTONS PGM2, PLG, RPL7 SSTR1 1203/4885SSTR2 970/4885SSTR4 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.